US EditionPublished • loading... • Updated
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
- HanchorBio presented Phase 1 clinical results of HCB101 at FACO 2025, indicating favorable safety and early antitumor activity.
- The presentation highlighted HCB101's strong receptor occupancy and confirmed responses in patients with advanced cancers.
- HCB101 is described as a novel SIRPα-engineered Fc fusion protein.
- FACO 2025 took place on October 24-25, 2025, in Shanghai, Mainland China.
Insights by Ground AI
32 Articles
32 Articles
The Billings Gazette+31 Reposted by 31 other sources
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers.
·Billings, United States
Read Full ArticleCoverage Details
Total News Sources32
Leaning Left3Leaning Right1Center14Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
L 17%
C 78%
Factuality
To view factuality data please Upgrade to Premium
